Two simian immunodeficiency virus strain mac (SIVmac)/human immunodeficiency virus type 1(HIV-1) chimeric viruses (SHIVs), designated NM-3 and NM-3n, with env derived from HIV-1 and defective vpr (plus defective nef for NM-3), were inoculated into seven macaques. These macaques were transiently or persistently infected and most of them produced long-lasting neutralizing antibodies and Env-specific killer T cells to HIV-1 with no AIDS-like symptoms. When they were challenged with another SHIV with intact vpr and nef (designated NM-3rN), all were protected as judged by virus recovery, DNA detection by PCR and antibody responses. Anti-HIV-1 Env-specific killer T cells were considered to have played a major role in this protection, but a non-specific defence mechanism as well as specific immunity also appeared to be involved. Thus, these two non-pathogenic SHIVs induced long-lasting protective immunities in macaques, suggesting the possibility of genedefective SHIVs as attenuated live vaccines for human use.
Two simian immunodeficiency virus strain mac (SIVmac)/human immunodeficiency virus type 1(HIV-1) chimeric viruses (SHIVs), designated NM-3
and NM-3n, with env derived from HIV-1 and defective vpr (plus defective nef for NM-3), were inoculated into seven macaques. These macaques were transiently or persistently infected and most of them produced long-lasting neutralizing antibodies and Env-specific killer T cells to HIV-1 with no AIDS-like symptoms. When they were challenged with another SHIV with intact vpr and nef (designated NM-3rN), all were protected as judged by virus recovery, DNA detection by PCR and antibody responses. Anti-HIV-1 Env-specific killer T cells were considered to have played a major role in this protection, but a non-specific defence mechanism as well as specific immunity also appeared to be involved. Thus, these two non-pathogenic SHIVs induced long-lasting protective immunities in macaques, suggesting the possibility of genedefective SHIVs as attenuated live vaccines for human use. Many attempts have been made to develop anti-human immunodeficiency virus type 1 (HIV-1) vaccines to control the AIDS pandemic. In the history of vaccines against viral diseases, such as poliomyelitis and measles, live-attenuated vaccines have proved to be the most effective by inducing long-lasting and strong humoral, cellular and other protective immunities. The possibility of developing live vaccines against HIV infection was suggested by the fact that monkeys immunized with a non-pathogenic simian immunodeficiency virus (SIV) were protected from challenge inoculation with virulent virus (Daniel et al., 1992 ; Clements et al., 1995) . In particular, the protection of macaques from a pathogenic SIVmac infection by inoculation with nef-deleted SIVmac by Daniel et al. introduced a new approach to attenuation of virus, i.e. deletion of gene(s) responsible for the onset of diseases.
Previously, we established an experimental system for evaluating the efficacy of anti-HIV-1 candidate vaccines that were designed to induce an immune response against Env. Because the only primate other than humans that can be infected with HIV-1 is the chimpanzee, and because chimpanzees are not readily available, two chimeric viruses (NM-3 and NM-3n), which infect macaque monkeys, were constructed. These SIVmac\HIV-1 chimeras consist of SIVmac and HIV-1, including HIV-1-derived Env and their use made it possible to use macaques instead of chimpanzees to test anti-HIV-1 vaccine candidates. NM-3 (Shibata et al., 1991) has defective vpr and nef, and NM-3n (Shibata et al., 1995) has defective vpr. nef and vpr functions have been associated with the potential to induce disease in SIVmac-infected macaques (Kestler et al., 1991 ; Lang et al., 1993) 
* These monkeys were infected with NM-3 by blood transfusion from MF1. † j, virus recovery at least once from periodically collected PBMC (Igarashi et al., 1994 (Igarashi et al., , 1996 . MF1, MM11 and MM13 showed persistent viraemia throughout the observation period. MF12 and MF15 showed transient viraemia for about 14 weeks. The virus was recovered from MF3096 twice (at 37 and 63 weeks) ; k, no virus recovery from MF3080 throughout the observation period before the challenge. ‡ j, successful virus recovery from PBMC just before challenge (MF1, MM11 and MM13) ; k, failure of virus recovery just before challenge (MF12, MF15, MF3080 and MF3096). § Antibody responses were assessed by Western immunoblot assay using the parental HIV-1-or SIVmacinfected cell lysates as antigens (Igarashi et al., 1994 (Igarashi et al., , 1996 . R NM-3 or NM-3n (100 TCID &! ) was treated with serum samples at a twofold serial dilution from the monkeys collected just before challenge. The highest serum dilution causing 50 % or more reduction of RT activity of the culture supernatants treated with a normal monkey serum was determined (Igarashi et al., 1994) . In MF1, the high neutralizing titre was maintained for about 2 years (from 10 weeks p.i. to the time of challenge). In MF3080 and MF3096, the neutralizing titre of over 80i was maintained for about 1n5 years. ¶ Baboon herpesvirus-transformed B cell lines established from each monkey PBMC sample were infected with an HIV-1 Env-expressing recombinant vaccinia virus and used as target cells. As control targets, the parental vaccinia virus-infected or non-infected cells were used. Cytotoxicity when the target was infected with the parental vacccinia virus is shown in parentheses. For the effector cells, autologous and heterologous PBMC were used. K562 cells were used as the target instead of autologous B cell lines for NK cell activity. These target and effector cells were mixed at various ratios (100 : 1-12n5 : 1) and target cell destruction was evaluated by release of &"Cr into the supernatant (Yamamoto et al., 1990) . As the degree of cytotoxicity was dependent on the target : effector cell ratio, a representative value at a ratio of 100 : 1 is shown in this table. Cytotoxicity over 20 % was regarded as significant. disease in neonatal monkeys infected with SIVmac lacking multiple genes including nef and vpr has been reported (Baba et al., 1995) . These SHIVs elicited neutralizing antibodies which could react not only with the SHIVs but also with the parental HIV-1, but did not cause AIDS-like symptoms (Igarashi et al., 1994 (Igarashi et al., , 1996 . Based on these results, we studied the possibility of using SHIVs with HIV-1-derived Env and defective vpr and\or nef as anti-HIV-1 live-attenuated vaccines for human use. These SHIVs have the added advantage that they also replicate well in human peripheral blood mononuclear cells (PBMC). Table 1 shows the viral and immunological status of the macaques, ' vaccinated ' with NM-3 or NM-3n, that were used in the present study. Six of the seven monkeys showed transient or persistent cell-associated viraemia during the primary infection (Igarashi et al., 1994 (Igarashi et al., , 1996 . All the monkeys raised anti-SIVmac Gag antibodies and five of the seven raised anti-HIV-1 Env antibodies as shown by Western immunoblotting. The sera containing anti-Env antibodies had virusneutralizing activity not only to the inoculated SHIVs (NM-3 or NM-3n), but also, at almost the same level, to the parental HIV-1 (Igarashi et al., 1996) . In the present study, we analysed cell-mediated immunity in these monkeys by using as target cells autologous PBMC which were infected with HIV-1 Envexpressing recombinant vaccinia virus by the method previously described (Yamamoto et al., 1990) . Five of the seven monkeys showed killer T cell activity ; this was considered to be HIV-1 Env-specific and MHC class I-restricted, because the cytotoxicity was higher than that obtained when similarly infected heterologous PBMC or autologous PBMC infected with the parental vaccinia virus were used as target cells. In addition, the cytotoxicity was considered to be CD8 + -cell- * The serially threefold diluted PBMC were cocultivated with human T-lymphoid M8166 cells for 4 weeks and examined for the appearance of immunofluorescent antigens and RT activities (Igarashi et al., 1994) . The cell-associated virus load was the number of cells yielding virus out of 1i10' CD8 + cell-depleted PBMC. † All the recovered viruses were identified by PCR amplification using primers specific to either NM-3 and NM-3n or NM-3rN. The sense primers were MVF (5h CAAAGGGAACCATGGGATGAATGGG 3h, nt 6440-6464 in MA239) and HVF (5h GAGCCATACAATGAATGGACACTAG-AGC 3h, nt 5595-5622 in NL432). The antisense primer used was UVR (5h CTGTCGAGTAACGCCTATTCTGCTATGTCG 3h, nt 5787-5816 in NL432). These primers were designed based on the flanking 5h recombination site of NM-3 and NM-3n. MVF anneals specifically to both the NM-3 and NM-3n sequences and does not anneal to the NM-3rN sequence. HVF anneals specifically to the NM-3rN sequence and not to the NM-3 and NM-3n sequences. Therefore, PCR using MVF and UVR can amplify only the NM-3 and NM-3n proviral DNA, whereas PCR using HVF and UVR can amplify the NM-3rN sequence alone. A 0n5 µg of sample extracted DNA from the virus-infected cells was used for PCR. ‡ The NM-3 vaccinated monkeys were euthanized at 18 or 21 weeks after challenge and their axillar, inguinal and mesenteric lymph nodes and spleens were subjected to virus recovery and proviral DNA detection by nested PCR using the primers specific for the vpr region. Inguinal lymph nodes of the NM-3n-vaccinated monkeys were biopsied and examined similarly. The sense primer for the first PCR was UVF (5h ATTGCAAGA-AAGGCTGTAGATGTCTAGGGG 3h, nt 6312-6341 in MA239) and the antisense primer used was HVR (5h CTGACTGTTCTGATGAGCTC-TTCGTCGC 3h, nt 5991-6018 in NL432). These primers anneal to all the SHIVs in this study. For the second PCR, the sense primer was either MVF or HVF, and the antisense primer was UVR. The viruses were recovered from the spleen of MF1 and the axillar lymph node of MM11. In addition, proviral DNA was detected in the spleen of MF15. All the recovered viruses and the detected proviral DNA were identifed as NM-3 by the differential PCR.
dependent, because the activity decreased when the effector cells were depleted of CD8 + cells (data not shown). The neutralizing antibody titres and killer T cell activities shown in Table 1 were determined after a rather long persistence (MF1, 3 years ; MF12, MF15, MM11 and MM13, 0n6 year ; MF3080 and MF3096, 2 years post-inoculation), and no clinical AIDSlike symptoms were observed. These results show that the vprand\or nef-defective SHIVs induced long-lasting humoral and cell-mediated immunity in the monkeys without causing disease. We challenged the seven vaccinated and four naive monkeys with an intravenous inoculation of 1i10& TCID &! NM-3rN (Kuwata et al., 1995) . NM-3rN, which has intact vpr and nef, is the most replication-competent SHIV and, although it has not yet induced AIDS-like disease, all the naive monkeys infected with NM-3rN showed persistent viraemia. Table 2 summarizes the results of the protection experiment. Infectious viruses were not recovered from three of the seven vaccinated monkeys (MF12, MF15 and MF3080) after the challenge. The cell-associated virus loads of the other four vaccinated monkeys were only about 1\10-1\100 of those of the naive controls. However, a differential PCR which amplifies vpr revealed that all the recovered viruses from these vaccinated monkeys were NM-3 or NM-3n, not NM-3rN. Between 10 and 20 weeks post-challenge, these vaccinated monkeys were euthanized, and virus recovery and PCR analysis were performed on lymph nodes and spleen. All the recovered viruses and the positive signals in PCR were also identified as NM-3, not NM-3rN. Table 3 shows the antibody responses of the monkeys assessed by particle agglutination after the challenge. All seven vaccinated monkeys except for MF12 possessed antibodies of rather high titre at the time of challenge. Five of these six monkeys did not show an anamnestic antibody response to the challenge. The other two monkeys, MF12 and MF3080, responded anamnestically. However, the antibody titre of T. Igarashi and others T. Igarashi and others MF12 surged at 2 weeks and declined rapidly, and that of MF3080 reached a plateau at 2 weeks and did not show any further increase. On the other hand, antibodies were first detected in naive monkeys at 4 or 8 weeks and then increased gradually.
These data indicate that all the monkeys vaccinated with the vpr-and\or nef-defective SHIVs (NM-3 or NM-3n) showed resistance to challenge inoculation with NM-3rN, which has intact vpr and nef. In particular, five of the seven monkeys showed sterilizing immunity. In the two other monkeys (MF12 and MF3080), NM-3rN probably transiently replicated, as suggested by their anamnestic antibody responses, but failed to establish infection.
Both neutralizing antibodies and the cytotoxic T cell activities against HIV-1 Env that were observed in most of the vaccinated monkeys might be involved in this protection. Regarding protection against SIV, there have been controversial reports on the role of neutralizing antibodies (Almond et al., 1995 ; Norley et al., 1996 ; Wyand et al., 1996) . In the protection observed in this study, it was noticed that one of the monkeys (MF15) with no detectable neutralizing antibody was completely protected. Cell-mediated immunity directed against Env probably played a more important role in this protection, because all five of the monkeys, including MF15 which had significant HIV-1 Env-specific killer T cells, showed sterilizing immunity.
In addition to HIV-1 Env-specific neutralizing antibodies and killer T cells, the contribution of natural killer (NK) cell activity was suggested by this study, because two vaccinated monkeys (MF12 and MF15) lacking detectable neutralizing antibodies and\or significant killer T cell activities but having high NK cell activity were protected. Not only do specific immunity mechanisms, such as neutralizing antibodies and killer T cell activity, play a role, but other specific and nonspecific defence mechanisms, such as antibody-dependent cellmediated cytotoxicity (ADCC) and NK cell activity, might also have a role. The ability to induce these complex protective mechanisms is an advantage of live-attenuated vaccines, which, in contrast to the current monovalent vaccine candidates, present viral components in replicative virions. Recent reports on attenuated SIV vaccines have pointed out that the efficacy of protection depended on the time between primary infection and challenge (Clements et al., 1995 ; Wyand et al., 1996) . We challenged the monkeys between 0n6 and 3n0 years after the primary infection. With these long incubation times, a complex defence mechanism consisting of not only specific immunity but also non-specific immunity might have developed. Based on these results, we propose that SHIVs with defective genes may be a good starting material for future live-attenuated HIV-1 vaccines. As these SHIVs replicate in human PBMC as well as macaque PBMC, they might be expected to replicate and induce protective immunities in humans as we observed them to do in monkeys in this study. Gene-deleted SHIVs may have another advantage, because they are also attenuated by the SIVmac portion of the chimeric structure, which is phylogenetically related to HIV-2. Viruses in the HIV-2 group are considered to be less pathogenic than HIV-1 in humans. In addition, the efficacy and safety of gene-deleted SHIVs can be evaluated with monkeys before application in humans.
